JPH0525857B2 - - Google Patents
Info
- Publication number
- JPH0525857B2 JPH0525857B2 JP63056522A JP5652288A JPH0525857B2 JP H0525857 B2 JPH0525857 B2 JP H0525857B2 JP 63056522 A JP63056522 A JP 63056522A JP 5652288 A JP5652288 A JP 5652288A JP H0525857 B2 JPH0525857 B2 JP H0525857B2
- Authority
- JP
- Japan
- Prior art keywords
- solution
- aqueous solution
- edta
- pharmaceutical composition
- vincristine sulfate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000243 solution Substances 0.000 claims abstract description 33
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims abstract description 27
- 150000003839 salts Chemical class 0.000 claims abstract description 26
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims abstract description 25
- 241000863480 Vinca Species 0.000 claims abstract description 23
- 239000000539 dimer Substances 0.000 claims abstract description 21
- 239000007864 aqueous solution Substances 0.000 claims abstract description 17
- 229960003415 propylparaben Drugs 0.000 claims abstract description 14
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims abstract description 12
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims abstract description 12
- 229960002216 methylparaben Drugs 0.000 claims abstract description 12
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims abstract description 12
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims abstract description 12
- 239000000203 mixture Substances 0.000 claims abstract description 11
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000008351 acetate buffer Substances 0.000 claims abstract description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
- 239000003755 preservative agent Substances 0.000 claims abstract description 8
- 230000002335 preservative effect Effects 0.000 claims abstract description 7
- AQTQHPDCURKLKT-JKDPCDLQSA-N vincristine sulfate Chemical group OS(O)(=O)=O.C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-JKDPCDLQSA-N 0.000 claims description 23
- 229960002110 vincristine sulfate Drugs 0.000 claims description 23
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 12
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 3
- 235000017281 sodium acetate Nutrition 0.000 claims description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 2
- 239000001632 sodium acetate Substances 0.000 claims description 2
- AYRVGWHSXIMRAB-UHFFFAOYSA-M sodium acetate trihydrate Chemical compound O.O.O.[Na+].CC([O-])=O AYRVGWHSXIMRAB-UHFFFAOYSA-M 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims 1
- 150000004684 trihydrates Chemical class 0.000 claims 1
- 229960001484 edetic acid Drugs 0.000 abstract description 3
- 238000003860 storage Methods 0.000 description 7
- 239000003814 drug Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 229920005862 polyol Polymers 0.000 description 4
- 150000003077 polyols Chemical class 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
- -1 amide derivative of vinblastine Chemical class 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
- 229960003048 vinblastine Drugs 0.000 description 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical class C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- 229960004355 vindesine Drugs 0.000 description 2
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- UKTNDLHXQNQKBH-UHFFFAOYSA-N 2,3-dihydro-1h-indole;1h-indole Chemical class C1=CC=C2NCCC2=C1.C1=CC=C2NC=CC2=C1 UKTNDLHXQNQKBH-UHFFFAOYSA-N 0.000 description 1
- BDKLKNJTMLIAFE-UHFFFAOYSA-N 2-(3-fluorophenyl)-1,3-oxazole-4-carbaldehyde Chemical compound FC1=CC=CC(C=2OC=C(C=O)N=2)=C1 BDKLKNJTMLIAFE-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- KCIDZIIHRGYJAE-YGFYJFDDSA-L dipotassium;[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] phosphate Chemical class [K+].[K+].OC[C@H]1O[C@H](OP([O-])([O-])=O)[C@H](O)[C@@H](O)[C@H]1O KCIDZIIHRGYJAE-YGFYJFDDSA-L 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 229940124274 edetate disodium Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 150000002730 mercury Chemical class 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229940087562 sodium acetate trihydrate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL83086A IL83086A (en) | 1987-07-06 | 1987-07-06 | Stable,injectable solutions of vincristine salts |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6416724A JPS6416724A (en) | 1989-01-20 |
| JPH0525857B2 true JPH0525857B2 (en]) | 1993-04-14 |
Family
ID=11057953
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP63056522A Granted JPS6416724A (en) | 1987-07-06 | 1988-03-11 | Stable and injectable vinca dimer salt solution |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US4883805A (en]) |
| EP (1) | EP0298192B1 (en]) |
| JP (1) | JPS6416724A (en]) |
| AT (1) | ATE65401T1 (en]) |
| CA (1) | CA1303992C (en]) |
| DE (1) | DE3863859D1 (en]) |
| ES (1) | ES2028917T3 (en]) |
| IL (1) | IL83086A (en]) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU204995B (en) * | 1989-11-07 | 1992-03-30 | Richter Gedeon Vegyeszet | Process for producing pharmaceutical composition comprising alkaloid with bis-indole skeleton, with antitumour activity and suitable fr parenteral purposes |
| GB9405593D0 (en) * | 1994-03-22 | 1994-05-11 | Zeneca Ltd | Pharmaceutical compositions |
| DE19818802A1 (de) * | 1998-04-27 | 1999-10-28 | Dresden Arzneimittel | Stabile Mitoxantron-Lösungen |
| US6849655B2 (en) | 2000-05-15 | 2005-02-01 | Kissei Pharmaceutical Co., Ltd. | Aqueous liquid formulations |
| US20020035107A1 (en) | 2000-06-20 | 2002-03-21 | Stefan Henke | Highly concentrated stable meloxicam solutions |
| US8992980B2 (en) | 2002-10-25 | 2015-03-31 | Boehringer Ingelheim Vetmedica Gmbh | Water-soluble meloxicam granules |
| WO2004091623A1 (en) | 2003-04-08 | 2004-10-28 | Progenics Pharmaceuticals. Inc. | Pharmaceutical formulations containing methylnaltrexone |
| FR2863891B1 (fr) * | 2003-12-23 | 2006-03-24 | Pf Medicament | Composition pharmaceutique de vinflunine destinee a une administration parentale, procede de preparation et utilisation |
| EP1568369A1 (en) | 2004-02-23 | 2005-08-31 | Boehringer Ingelheim Vetmedica Gmbh | Use of meloxicam for the treatment of respiratory diseases in pigs |
| TWI489984B (zh) | 2006-08-04 | 2015-07-01 | Wyeth Corp | 用於非經腸道傳輸化合物之配方及其用途 |
| US7923037B2 (en) * | 2006-10-05 | 2011-04-12 | Ikaria, Inc. | Liquid chalcogenide compositions and methods of manufacturing and using the same |
| JP6099557B2 (ja) * | 2013-12-27 | 2017-03-22 | 富士フイルム株式会社 | 注射液製剤及びその製造方法 |
| EP3328385B1 (en) * | 2015-08-01 | 2020-07-08 | Sun Pharmaceutical Industries Ltd | Dosage form of vinca alkaloid drug |
| CN114699369A (zh) * | 2022-05-19 | 2022-07-05 | 青岛农业大学 | 一种盐酸溴己新注射液及其制备方法和应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3248291A (en) * | 1963-08-19 | 1966-04-26 | Hoffmann La Roche | Stabilized thioxanthene derivatives and method of using the same |
| GB1254057A (en) * | 1969-04-24 | 1971-11-17 | Louisette Olivier | Improvements in or relating to therapeutical composition containing vincamine |
| GB2020180B (en) * | 1978-05-08 | 1982-08-25 | Nelson Res & Dev | Ophthalmic compositions containingcolchicine or vinblastinr |
| US4619935A (en) * | 1983-03-17 | 1986-10-28 | Eli Lilly And Company | Stable oncolytic formulations |
| US4708962A (en) * | 1984-12-17 | 1987-11-24 | Harbor Branch Oceanographic Institution, Inc. | Antiviral and antitumor cyclohexadienone compositions |
| US4707498A (en) * | 1986-01-14 | 1987-11-17 | Merrell Dow Pharmaceuticals Inc. | Fluorinated diaminoalkyne derivatives |
-
1987
- 1987-07-06 IL IL83086A patent/IL83086A/xx unknown
- 1987-07-28 US US07/078,805 patent/US4883805A/en not_active Expired - Fee Related
-
1988
- 1988-03-01 DE DE8888103072T patent/DE3863859D1/de not_active Expired - Lifetime
- 1988-03-01 EP EP88103072A patent/EP0298192B1/en not_active Expired - Lifetime
- 1988-03-01 AT AT88103072T patent/ATE65401T1/de not_active IP Right Cessation
- 1988-03-01 ES ES198888103072T patent/ES2028917T3/es not_active Expired - Lifetime
- 1988-03-07 CA CA000560733A patent/CA1303992C/en not_active Expired - Lifetime
- 1988-03-11 JP JP63056522A patent/JPS6416724A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| ES2028917T3 (es) | 1992-07-16 |
| IL83086A0 (en) | 1987-12-31 |
| DE3863859D1 (de) | 1991-08-29 |
| US4883805A (en) | 1989-11-28 |
| ATE65401T1 (de) | 1991-08-15 |
| EP0298192B1 (en) | 1991-07-24 |
| AU604094B2 (en) | 1990-12-06 |
| IL83086A (en) | 1991-03-10 |
| AU1257888A (en) | 1989-01-12 |
| EP0298192A1 (en) | 1989-01-11 |
| JPS6416724A (en) | 1989-01-20 |
| CA1303992C (en) | 1992-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002352105B2 (en) | Platinum derivative pharmaceutical formulations | |
| EP0652751B1 (en) | Injection and injection kit containing omeprazole and its analogs | |
| JPH0525857B2 (en]) | ||
| JP5710462B2 (ja) | 非経口投与を目的とするビンフルニンの医薬組成物、その調製方法およびその使用 | |
| CN106963759B (zh) | 用于治疗过度增生性疾病、自身免疫性疾病和心脏病的包含3-奎宁环酮衍生物的水溶液 | |
| ZA200200800B (en) | Pharmaceutically stable oxaliplatinum preparation for parenteral administration. | |
| EP0215596A2 (en) | Composition for injection of active type vitamins D3 | |
| JP2020125359A (ja) | ペメトレキセドまたはその薬剤学的に許容可能な塩を含有する安定化された薬学組成物 | |
| JPH04503070A (ja) | プラスミノーゲン活性化因子蛋白の薬学的組成物 | |
| SG193932A1 (en) | Otamixaban formulations with improved stability | |
| JPH06247872A (ja) | 高濃度ｔｃｆ製剤 | |
| EP0659435B1 (en) | Injectable ready-to-use solutions containing Doxorubicin | |
| JP4956942B2 (ja) | 安定化された注射用水溶液製剤 | |
| JP3720262B2 (ja) | 安定化したカルベジロール注射溶液 | |
| RU2449791C2 (ru) | Лиофилизированная инъецируемая фармацевтическая композиция полусинтетических алкалоидов vinca и углевода, стабильная при комнатной температуре | |
| HU191538B (en) | Process for producing pharmaceutical compositions containing acid additional salts of vinca-dimeres | |
| EP0348150A2 (en) | Use of thromboxane receptor antagonist in renal diseases and dysfunction | |
| JP2000219628A (ja) | アラトロフロキサシンの予め混合した注射用組成物 | |
| US4425348A (en) | Antitumor compositions | |
| JP2946015B2 (ja) | 安定な抗ウィルス点滴用注射剤 | |
| EP0063434B1 (en) | Pharmaceutical composition comprising a penicillin derivative for the treatment of bacterial infections | |
| JPS6334844B2 (en]) | ||
| HK1011288B (en) | Injectable ready-to-use solutions containing doxorubicin | |
| JPS6334126B2 (en]) | ||
| JPS6344126B2 (en]) |